LSU Health Shreveport Feist-Weiller Cancer Center’s resident physicians now have access to high-precision medical technology designed to identify the distinctive characteristics of each cancer patient’s tumor. Access to this information will allow doctors to better personalize cancer treatment options such as chemo and radiation therapies. This new patient-centered feature will be made possible by a novel advancement called “tumor profiling.” Feist-Weiller will be collaborating with Irving, Texas-based Caris Life Sciences to give patients and healthcare professionals at University Health Shreveport — LSU Health Shreveport School of Medicine’s clinical partner — access to this new approach to cancer care.
The new service will utilize Caris Life Sciences’ own pioneering tumor profiling platform, Caris Molecular Intelligence™, in order to elevate Feist-Weiller Cancer Center’s position in clinical and research proficiency. This partnership will help to bolster the center’s patient-centered care method by making cancer management and treatment a more tailored experience for patients, and will cover clinical support, education for both patients and doctors, and system integration.
Glenn Mills, M.D., F.A.C.P., the Director and a professor at Feist-Weiller Cancer Center, noted in a recent press release that he takes pride in the center being the only facility within a 250 mile radius to offer this service, and gives recognition to Caris for making high-precision and personalized cancer care possible.
Cherie-Ann O. Nathan, M.D., FACS, Chairman and Professor, Director of Head and Neck Surgical Oncology and Research, said that this new molecular technology will contribute significantly to the enhancement of the quality of care given to patients at the center, as well as elevate its research initiatives.
Over the past few years, the concept behind Caris’ technological advancement has steadily gained popularity among oncologists as a highly effective method in prescribing appropriate cancer management and treatment, especially for those fighting the rarer and more aggressive types of malignancies. Caris Molecular Intelligence makes it easier to compare identified molecular information from tumors with biomarker or drug associations from the most recent and relevant literature. The information gathered will not only help to recommend treatments, but also develop compatible clinical trials as well.
David D. Halbert, the Chairman and CEO of Caris Life Sciences, said that this technology and their partnership with LSU’s Feist-Weiller Cancer Center will help make oncologists’ crucial decisions easier and more definitive.
Just last June, BioNews Texas published a report on a tumor-profiling ovarian cancer therapy approach from Caris Life Sciences that was shown to increase survival rates.